The laboratory is interested in the development of next-generation cancer chemotherapeutics by targeting protein-protein interaction interfaces inside cancer cells. The idea is to have a targeted therapy that would have less toxic side effects in contrast to the clinically used chemotherapeutics.
The precise understanding of the role of proteins in signal transduction cascades involves their selective perturbation at defined time points. Target specific cell-permeable chemical tools are perfectly suited to reversibly perturb signal transduction events in live cells. Thus, the laboratory is actively engaged in developing chemical perturbants and studies their role in signal transduction events.
Peptides are great candidates as “leads” towards their development as drugs. However, their in vivo efficacy is remarkably compromised owing to their metabolic instability. Thus, the laboratory is actively seeking strategies to enhance metabolic stabilities of peptide-based ligands.